<DOC>
	<DOCNO>NCT01529294</DOCNO>
	<brief_summary>This study aim determine pharmacokinetic profile tolerability iloperidone subject mild moderate hepatic impairment comparatively healthy match subject</brief_summary>
	<brief_title>Single-dose Iloperidone Pharmacokinetics Patients With Mild Moderate Liver Disease , Compared Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion criterion ( subject ) : Caucasian subject Inclusion criterion ( hepatic impaired subject ) : subject physical sign consistent clinical diagnosis stable liver disease , confirm image technique , ultrasound , Magnetic Resonance Imaging Computed Tomogram within 3 month screen , creatinine clearance &gt; 50 mL/min ( base Cockroft Gault formula ) . Inclusion criterion ( healthy volunteer ) : good general health match age , gender , smoke status , Body Mass Index , CYP2D6 phenotype hepatic impaired subject . Exclusion criterion ( subject ) : Subjects report smoke pipe , cigars 20 cigarette per day . History drug abuse define Diagnostic Statistical Manual Mental Disorders , Diagnostic Criteria Drug Alcohol Abuse , within 12 month prior screen History firstdose response/syncope alpha1blocking agent Exclusion criterion ( Hepatic impair subject ) : Patients symptoms 6 month past history encephalopathy . Patients clinical evidence moderatesevere ascites . Patients previous surgical portosystemic shunt . Exclusion criterion ( Healthy volunteer ) : History alcohol abuse prior dosing , evidence abuse screening . Pulse Rate &gt; 200 msec Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Iloperidone</keyword>
	<keyword>ILO522D</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>